Miaomiao Gou

Fuxing Road 28
Haidian, 100853, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 28 publications

Fluorescent Multiplex Immunohistochemistry (mIHC) Analyses of Local Advanced Gastric Cancer Patients After Neoadjuvant Chemotherapy Revealed the Status of Tumor-Infiltrating Immune Cells and Predicted the Clinical Outcome.

Fluorescent Multiplex Immunohistochemistry (mIHC) Analyses of Local Advanced Gastric Cancer Patients After Neoadjuvant Chemotherapy Revealed the Status of Tumor-Infiltrating Immune Cells and Predicted the Clinical Outcome.

Journal: Cancer medicine

Published: October 13, 2025

Exploration of the benefits and resistance mechanisms of immunotherapy based on PD-L1 expression, circulating tumor DNA and T-cell receptor profiles in advanced gastric cancer.

Exploration of the benefits and resistance mechanisms of immunotherapy based on PD-L1 expression, circulating tumor DNA and T-cell receptor profiles in advanced gastric cancer.

Journal: Cancer immunology, immunotherapy : CII

Published: June 09, 2025

Combined Chemotherapy-Immunotherapy for Advanced Biliary Tract Cancer (BTC): A Clinical, Genomic, and Biomarker Analysis.

Combined Chemotherapy-Immunotherapy for Advanced Biliary Tract Cancer (BTC): A Clinical, Genomic, and Biomarker Analysis.

Journal: Journal of gastrointestinal cancer

Published: March 25, 2025

miR-196b strictly regulates and reliably predicts the response to cetuximab in colorectal cancer.

miR-196b strictly regulates and reliably predicts the response to cetuximab in colorectal cancer.

Journal: Cellular & molecular biology letters

Published: January 08, 2025

Single-cell sequencing analysis reveals cetuximab resistance mechanism and salvage strategy in colorectal cancer.

Single-cell sequencing analysis reveals cetuximab resistance mechanism and salvage strategy in colorectal cancer.

Journal: Clinical and translational medicine

Published: October 04, 2024

Third- or Further-Line Treatment in Patients with MSS Type Metastatic Colorectal Cancer.

Third- or Further-Line Treatment in Patients with MSS Type Metastatic Colorectal Cancer.

Journal: Journal of gastrointestinal cancer

Published: September 29, 2024

Comprehensive Analysis and Experimental Validation of HEPACAM2 as a Potential Prognosis Biomarker and Immunotherapy Target in Colorectal Cancer.

Comprehensive Analysis and Experimental Validation of HEPACAM2 as a Potential Prognosis Biomarker and Immunotherapy Target in Colorectal Cancer.

Journal: Current gene therapy

Published: May 18, 2024

PD-1 inhibitor combined with albumin paclitaxel and apatinib as second-line treatment for patients with metastatic gastric cancer: a single-center, single-arm, phase II study.

PD-1 inhibitor combined with albumin paclitaxel and apatinib as second-line treatment for patients with metastatic gastric cancer: a single-center, single-arm, phase II study.

Journal: Investigational new drugs

Published: December 14, 2023

Prognostic value of the Lung Immune Prognostic Index for HER-2-negative metastatic gastric cancer.

Prognostic value of the Lung Immune Prognostic Index for HER-2-negative metastatic gastric cancer.

Journal: Biomarkers in medicine

Published: December 12, 2023

PD-1 inhibitors-based second-line therapy for metastatic gastric cancer.

PD-1 inhibitors-based second-line therapy for metastatic gastric cancer.

Journal: Frontiers in immunology

Published: January 04, 2023

Pretreatment platelet-to-lymphocyte ratio (PLR) as a prognosticating indicator for gastric cancer patients receiving immunotherapy.

Pretreatment platelet-to-lymphocyte ratio (PLR) as a prognosticating indicator for gastric cancer patients receiving immunotherapy.

Journal: Discover oncology

Published: September 19, 2022

A composite indicator of derived neutrophil-lymphocyte ratio and lactate dehydrogenase correlates with outcomes in pancreatic carcinoma patients treated with PD-1 inhibitors.

A composite indicator of derived neutrophil-lymphocyte ratio and lactate dehydrogenase correlates with outcomes in pancreatic carcinoma patients treated with PD-1 inhibitors.

Journal: Frontiers in oncology

Published: May 24, 2022

Showing 1-12 of 28

Last Updated: 09/26/2026